急性缺血性卒中静脉溶栓中外周血炎症指标与预后的研究进展

doi:10.3969/j.issn.1673-5765.2026.01.006

中国卒中杂志 ›› 2026, Vol. 21 ›› Issue (1): 55-64.DOI: 10.3969/j.issn.1673-5765.2026.01.006

急性缺血性卒中静脉溶栓中外周血炎症指标与预后的研究进展

何丹丹^1，2，李姝雅^1，3，4

1北京 100070 首都医科大学附属北京天坛医院临床试验中心
2北京 100070 首都医科大学临床流行病学与临床试验学系
3北京 100070 首都医科大学附属北京天坛医院神经系统疾病国家临床医学研究中心
4北京 100070 首都医科大学附属北京天坛医院神经病学中心

收稿日期:2025-10-09 修回日期:2026-01-12 接受日期:2026-01-17 出版日期:2026-01-20 发布日期:2026-01-20
通讯作者: 李姝雅 shuyali85@163.com
基金资助:
国家自然科学基金青年科学基金项目（B类）（82522025）

Research Progress on Peripheral Blood Inflammatory Indices and Prognosis in Intravenous Thrombolysis for Acute Ischemic Stroke

HE Dandan^1,2, LI Shuya^1,3,4

1Department of Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China 2Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing 100070, China 3China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China 4Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Received:2025-10-09 Revised:2026-01-12 Accepted:2026-01-17 Online:2026-01-20 Published:2026-01-20
Contact: LI Shuya, E-mail: shuyali85@163.com

摘要/Abstract

摘要： 静脉溶栓是急性缺血性卒中（acute ischemic stroke, AIS）的重要再灌注治疗措施，但部分患者仍面临静脉溶栓后功能预后欠佳及出血风险增加的困境。炎症反应在AIS的病理生理过程中发挥重要作用，其不仅参与缺血性脑损伤的发生和发展，还影响静脉溶栓的效果和安全性。外周血炎症指标因具有便捷、经济且可动态监测的优势，在AIS患者预后评估方面具有潜在的应用价值。本文系统阐述了AIS发生后的炎症反应机制及相关抗炎治疗研究进展，并梳理了静脉溶栓中常用的炎症指标（如中性粒细胞与淋巴细胞比值、系统性炎症反应指数、血小板与淋巴细胞比值等）与患者预后的关联，以期为基于炎症指标筛选AIS抗炎治疗的潜在获益人群提供参考。

文章导读： 本文系统总结了接受静脉溶栓的急性缺血性卒中患者的炎症反应机制及相关抗炎药物的研究进展，重点分析了外周血炎症指标（如中性粒细胞与淋巴细胞比值、系统性免疫炎症指数等）在患者预后评估中的重要性。研究结果表明，上述炎症指标与不良功能结局、出血风险及死亡率密切相关，可作为优化急性缺血性卒中后个体化管理和筛选抗炎治疗潜在获益人群的生物标志物。

关键词: 急性缺血性卒中; 炎症指标; 静脉溶栓

Abstract: Intravenous thrombolysis is an important reperfusion therapy for acute ischemic stroke (AIS). However, some patients still face challenges such as poor functional prognosis and increased risk of bleeding after intravenous thrombolysis. Inflammatory responses play a crucial role in the pathophysiological process of AIS. They not only contribute to the occurrence and development of ischemic brain injury, but also affect the efficacy and safety of intravenous thrombolysis. Due to their convenience, cost-effectiveness, and ability to be dynamically monitored, peripheral blood inflammatory indices have shown significant potential value in prognostic assessment of AIS patients. This article systematically elucidates the mechanisms of inflammatory responses after AIS onset and the research progress of related anti-inflammatory therapies. It also reviews the associations between commonly used inflammatory indices in intravenous thrombolysis (such as the neutrophil-to-lymphocyte ratio, systemic inflammatory response index, and platelet-to-lymphocyte ratio) and patient prognosis, providing a reference for selecting potential beneficiaries of anti-inflammatory therapy in AIS based on inflammatory indices.

Key words: Acute ischemic stroke; Inflammatory index; Intravenous thrombolysis

中图分类号:

何丹丹, 李姝雅. 急性缺血性卒中静脉溶栓中外周血炎症指标与预后的研究进展[J]. 中国卒中杂志, 2026, 21(1): 55-64.

HE Dandan, LI Shuya. Research Progress on Peripheral Blood Inflammatory Indices and Prognosis in Intravenous Thrombolysis for Acute Ischemic Stroke[J]. Chinese Journal of Stroke, 2026, 21(1): 55-64.

参考文献

[1] GBD 2021 Stroke Risk Factor Collaborators. Global，regional，and national burden of stroke and its risk factors，1990-2021：a systematic analysis for the global burden of disease study 2021[J]. Lancet Neurol，2024，23（10）：973-1003.
[2] Institute for Health Metrics and Evaluation（IHME）. GBD results[EB/OL].（2025-10-12）[2026-01-08]. https://www.healthdata.org/data-tools-practices/interactive-visuals/gbd-results.
[3] WANG M，WANG C J，GU H Q，et al. Sex differences in short-term and long-term outcomes among patients with acute ischemic stroke in China[J]. Stroke，2022，53（7）：2268-2275.
[4] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2019，50（12）：e344-e418[2025-12-30]. https://doi.org/10.1161/STR.0000000000000211.
[5] WARDLAW J M，MURRAY V，BERGE E，et al. Thrombolysis for acute ischaemic stroke[J/OL]. Cochrane Database Syst Rev，2014（7）：CD000213[2025-12-30]. https://doi.org/10.1002/14651858.CD000213.pub3.
[6] IADECOLA C，BUCKWALTER M S，ANRATHER J. Immune responses to stroke：mechanisms，modulation，and therapeutic potential[J]. J Clin Invest，2020，130（6）：2777-2788.
[7] MAIDA C D，NORRITO R L，DAIDONE M，et al. Neuroinflammatory mechanisms in ischemic stroke：focus on cardioembolic stroke，background，and therapeutic approaches[J/OL]. Int J Mol Sci，2020，21（18）：6454[2025-12-30]. https://doi.org/10.3390/ijms21186454.
[8] ZHAO J R，DONG L P，HUI S，et al. Prognostic values of prothrombin time and inflammation-related parameter in acute ischemic stroke patients after intravenous thrombolysis with rt-PA[J/OL]. Clin Appl Thromb Hemost，2023，29：10760296231198042[2025-12-30]. https://doi.org/10.1177/10760296231198042.
[9] MERALI Z，HUANG K，MIKULIS D，et al. Evolution of blood-brain-barrier permeability after acute ischemic stroke[J/OL]. PLoS One，2017，12（2）：e0171558[2025-12-30]. https://doi.org/10.1371/journal.pone.0171558.
[10] QIU Y M，ZHANG C L，CHEN A Q，et al. Immune cells in the BBB disruption after acute ischemic stroke：targets for immune therapy？[J/OL]. Front Immunol，2021，12：678744[2025-12-30]. https://doi.org/10.3389/fimmu.2021.678744.
[11] XIE J L，PANG C Y，YU H，et al. Leukocyte indicators and variations predict worse outcomes after intravenous thrombolysis in patients with acute ischemic stroke[J]. J Cereb Blood Flow Metab，2023，43（3）：393-403.
[12] SHI K B，TIAN D C，LI Z G，et al. Global brain inflammation in stroke[J]. Lancet Neurol，2019，18（11）：1058-1066.
[13] ANRATHER J，IADECOLA C. Inflammation and stroke：an overview[J]. Neurotherapeutics，2016，13（4）：661-670.
[14] PRASS K，MEISEL C，HÖFLICH C，et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation[J]. J Exp Med，2003，198（5）：725-736.
[15] GHELANI D P，KIM H A，ZHANG S R，et al. Ischemic stroke and infection：a brief update on mechanisms and potential therapies[J/OL]. Biochem Pharmacol，2021，193：114768[2025-12-30]. https://doi.org/10.1016/j.bcp.2021.114768.
[16] DRAXLER D F，LEE F，HO H，et al. t-PA suppresses the immune response and aggravates neurological deficit in a murine model of ischemic stroke[J/OL]. Front Immunol，2019，10：591[2025-12-30]. https://doi.org/10.3389/fimmu.2019.00591.
[17] CHEN C，CHU S F，LIU D D，et al. Chemokines play complex roles in cerebral ischemia[J/OL]. Neurochem Int，2018，112：146-158[2025-12-30]. https://doi.org/10.1016/j.neuint.2017.06.008.
[18] CAI W，LIU S X，HU M Y，et al. Functional dynamics of neutrophils after ischemic stroke[J]. Transl Stroke Res，2020，11（1）：108-121.
[19] BEUKER C，STRECKER J K，RAWAL R，et al. Immune cell infiltration into the brain after ischemic stroke in humans compared to mice and rats：a systematic review and meta-analysis[J]. Transl Stroke Res，2021，12（6）：976-990.
[20] JICKLING G C，LIU D Z，ANDER B P，et al. Targeting neutrophils in ischemic stroke：translational insights from experimental studies[J]. J Cereb Blood Flow Metab，2015，35（6）：888-901.
[21] XIE M Z，HAO Y L，FENG L S，et al. Neutrophil heterogeneity and its roles in the inflammatory network after ischemic stroke[J]. Curr Neuropharmacol，2023，21（3）：621-650.
[22] LIAO B Y，GENG L L，ZHANG F，et al. Adipocyte fatty acid-binding protein exacerbates cerebral ischaemia injury by disrupting the blood-brain barrier[J]. Eur Heart J，2020，41（33）：3169-3180.
[23] LENGLET S，MONTECUCCO F，DENES A，et al. Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice[J]. J Cereb Blood Flow Metab，2014，34（5）：802-812.
[24] MONTANER J，MOLINA C A，MONASTERIO J，et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke[J]. Circulation，2003，107（4）：598-603.
[25] JIMÉNEZ-ALCÁZAR M，KIM N，FUCHS T A. Circulating extracellular DNA：cause or consequence of thrombosis？[J]. Semin Thromb Hemost，2017，43（6）：553-561.
[26] LI Q C，YE J，LI Z F，et al. The role of neutrophils in tPA thrombolysis after stroke：a malicious troublemaker[J/OL]. Front Immunol，2024，15：1477669[2025-12-30]. https://doi.org/10.3389/fimmu.2024.1477669.
[27] SHI K B，ZOU M，JIA D M，et al. tPA mobilizes immune cells that exacerbate hemorrhagic transformation in stroke[J]. Circ Res，2021，128（1）：62-75.
[28] SHI J，PENG H，YOU S，et al. Increase in neutrophils after recombinant tissue plasminogen activator thrombolysis predicts poor functional outcome of ischaemic stroke：a longitudinal study[J/OL]. Eur J Neurol，2018，25（4）：687-e45[2025-12-30]. https://doi.org/10.1111/ene.13575.
[29] YING A N，CHENG Y N，LIN Y Y，et al. Dynamic increase in neutrophil levels predicts parenchymal hemorrhage and function outcome of ischemic stroke with r-tPA thrombolysis[J]. Neurol Sci，2020，41（8）：2215-2223.
[30] LEUNG Y Y，YAO HUI L L，KRAUS V B. Colchicine—update on mechanisms of action and therapeutic uses[J]. Semin Arthritis Rheum，2015，45（3）：341-350.
[31] KELLY P，LEMMENS R，WEIMAR C，et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke（CONVINCE）：a randomised controlled trial[J]. Lancet，2024，404（10448）：125-133.
[32] LI J J，MENG X，SHI F D，et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack（CHANCE-3）：multicentre，double blind，randomised，placebo controlled trial[J/OL]. BMJ，2024，385：e079061[2025-12-30]. https://doi.org/10.1136/bmj-2023-079061.
[33] MACHADO L S，SAZONOVA I Y，KOZAK A，et al. Minocycline and tissue-type plasminogen activator for stroke：assessment of interaction potential[J]. Stroke，2009，40（9）：3028-3033.
[34] FAGAN S C，WALLER J L，NICHOLS F T，et al. Minocycline to improve neurologic outcome in stroke（MINOS）：a dose-finding study[J]. Stroke，2010，41（10）：2283-2287.
[35] KRAMS M，LEES K R，HACKE W，et al. Acute stroke therapy by inhibition of neutrophils（ASTIN）：an adaptive dose-response study of UK-279，276 in acute ischemic stroke[J]. Stroke，2003，34（11）：2543-2548.
[36] Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke：results of the enlimomab acute stroke trial[J]. Neurology，2001，57（8）：1428-1434.
[37] GELDERBLOM M，LEYPOLDT F，STEINBACH K，et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke[J]. Stroke，2009，40（5）：1849-1857.
[38] MEISEL C，SCHWAB J M，PRASS K，et al. Central nervous system injury-induced immune deficiency syndrome[J]. Nat Rev Neurosci，2005，6（10）：775-786.
[39] XIAO J，QIU Q W，QIN C，et al. Dynamic changes of peripheral blood lymphocyte subsets in acute ischemic stroke and prognostic value[J/OL]. Brain Behav，2020，11（1）：e01919[2025-12-30]. https://doi.org/10.1002/brb3.1919.
[40] BECKER K，KINDRICK D，RELTON J，et al. Antibody to the α4 integrin decreases infarct size in transient focal cerebral ischemia in rats[J]. Stroke，2001，32（1）：206-211.
[41] ELKIND M S V，VELTKAMP R，MONTANER J，et al. Natalizumab in acute ischemic stroke（ACTION Ⅱ）[J/OL]. Neurology，2020，95（8）：e1091-e1104[2025-12-28]. https://doi.org/10.1212/WNL.0000000000010038.
[42] ELKINS J，VELTKAMP R，MONTANER J，et al. Safety and efficacy of natalizumab in patients with acute ischaemic stroke（ACTION）：a randomised，placebo-controlled，double-blind phase 2 trial[J]. Lancet Neurol，2017，16（3）：217-226.
[43] MASSBERG S，VON ANDRIAN U H. Fingolimod and sphingosine-1-phosphate—modifiers of lymphocyte migration[J]. N Engl J Med，2006，355（11）：1088-1091.
[44] SCHWAB S R，PEREIRA J P，MATLOUBIAN M，et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients[J]. Science，2005，309（5741）：1735-1739.
[45] TIAN D C，SHI K B，ZHU Z L，et al. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow[J]. Ann Neurol，2018，84（5）：717-728.
[46] FU Y，ZHANG N N N，REN L，et al. Impact of an immune modulator fingolimod on acute ischemic stroke[J]. Proc Natl Acad Sci U S A，2014，111（51）：18315-18320.
[47] ZHU Z L，FU Y，TIAN D C，et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke：a pilot trial[J]. Circulation，2015，132（12）：1104-1112.
[48] KOVACS-LITMAN A，VONDERWALDE I. Monocyte-derived macrophages modulate inflammation and promote long-term functional recovery in a mouse model of ischemia[J]. J Neurosci，2016，36（38）：9757-9759.
[49] GILL D，SIVAKUMARAN P，ARAVIND A，et al. Temporal trends in the levels of peripherally circulating leukocyte subtypes in the hours after ischemic stroke[J]. J Stroke Cerebrovasc Dis，2018，27（1）：198-202.
[50] SRIVASTAVA P，CRONIN C G，SCRANTON V L，et al. Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4（P2X4R）blockade after ischemic stroke[J/OL]. Exp Neurol，2020，329：113308[2025-12-28]. https://doi.org/10.1016/j.expneurol.2020.113308.
[51] SHARMIN O，ABIR A H，POTOL A，et al. Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages[J/OL]. Sci Rep，2020，10：9400[2025-12-28]. https://doi.org/10.1038/s41598-020-66417-8.
[52] NAVARRO S，BOIX E，CUCHILLO C M，et al. Eosinophil-induced neurotoxicity：the role of eosinophil cationic protein/RNase 3[J]. J Neuroimmunol，2010，227（1/2）：60-70.
[53] CODEN M E，BERDNIKOVS S. Eosinophils in wound healing and epithelial remodeling：is coagulation a missing link？[J]. J Leukoc Biol，2020，108（1）：93-103.
[54] BOLTON S J，MCNULTY C A，THOMAS R J，et al. Expression of and functional responses to protease-activated receptors on human eosinophils[J]. J Leukoc Biol，2003，74（1）：60-68.
[55] YANG D H，HUANG H H，WENG Y Y，et al. Dynamic decrease in eosinophil after intravenous thrombolysis predicts poor prognosis of acute ischemic stroke：a longitudinal study[J/OL]. Front Immunol，2021，12：709289[2025-12-28]. https://doi.org/10.3389/fimmu.2021.709289.
[56] WANG A X，QUAN K H，TIAN X，et al. Leukocyte subtypes and adverse clinical outcomes in patients with acute ischemic cerebrovascular events[J/OL]. Ann Transl Med，2021，9（9）：748[2025-12-28]. https://doi.org/10.21037/atm-20-7931.
[57] ZHU F，WANG Z H，SONG J H，et al. Correlation analysis of inflammatory markers with the short-term prognosis of acute ischaemic stroke[J/OL]. Sci Rep，2024，14：17772[2025-12-28]. https://doi.org/10.1038/s41598-024-66279-4.
[58] SHARMA D，SPRING K J，BHASKAR S M M. Role of neutrophil-lymphocyte ratio in the prognosis of acute ischaemic stroke after reperfusion therapy：a systematic review and meta-analysis[J/OL]. J Cent Nerv Syst Dis，2022，14：11795735221092518[2025-12-28]. https://doi.org/10.1177/11795735221092518.
[59] MA F，LI L L，XU L，et al. The relationship between systemic inflammation index，systemic immune-inflammatory index，and inflammatory prognostic index and 90-day outcomes in acute ischemic stroke patients treated with intravenous thrombolysis[J/OL]. J Neuroinflammation，2023，20：220[2025-12-28]. https://doi.org/10.1186/s12974-023-02890-y.
[60] HAN J，YANG L T，LOU Z C，et al. Association between systemic immune-inflammation index and systemic inflammation response index and outcomes of acute ischemic stroke：a systematic review and meta-analysis[J]. Ann Indian Acad Neurol，2023，26（5）：655-662.
[61] WANG M Q，SUN Y Y，WANG Y，et al. Platelet-to-neutrophil ratio after intravenous thrombolysis predicts unfavorable outcomes in acute ischemic stroke[J]. Curr Neurovasc Res，2020，17（4）：411-419.
[62] SUN Y Y，WANG M Q，WANG Y，et al. Platelet-to-lymphocyte ratio at 24 h after thrombolysis is a prognostic marker in acute ischemic stroke patients[J/OL]. Front Immunol，2022，13：1000626[2025-12-28]. https://doi.org/10.3389/fimmu.2022.1000626.
[63] GAO B B，PAN W J，HU X T，et al. Neutrophil-related ratios predict the 90-day outcome in acute ischemic stroke patients after intravenous thrombolysis[J/OL]. Front Physiol，2021，12：670323[2025-12-28]. https://doi.org/10.3389/fphys.2021.670323.
[64] CAI H Y，HUANG H H，YANG C G，et al. Eosinophil-to-neutrophil ratio predicts poor prognosis of acute ischemic stroke patients treated with intravenous thrombolysis[J/OL]. Front Neurol，2021，12：665827[2025-12-28]. https://doi.org/10.3389/fneur.2021.665827.
[65] CHEN Y P，REN J L，YANG N P，et al. Eosinophil-to-monocyte ratio is a potential predictor of prognosis in acute ischemic stroke patients after intravenous thrombolysis[J/OL]. Clin Interv Aging，2021，16：853-862[2025-12-28]. https://doi.org/10.2147/CIA.S309923.
[66] LI G S，HAO Y H，WANG C Y，et al. Association between neutrophil-to-lymphocyte ratio/lymphocyte-to-monocyte ratio and in-hospital clinical outcomes in ischemic stroke treated with intravenous thrombolysis[J/OL]. J Inflamm Res，2022，15：5567-5578[2025-12-28]. https://doi.org/10.2147/JIR.S382876.
[67] SONG Q H，PAN R S，JIN Y X，et al. Lymphocyte-to-monocyte ratio and risk of hemorrhagic transformation in patients with acute ischemic stroke[J]. Neurol Sci，2020，41（9）：2511-2520.
[68] ZHANG A M，ZHU Y，LIAO J Q，et al. The association of systemic inflammatory response index and neutrophil-to-high-density lipoprotein ratio mediated by fasting blood glucose with 90-day prognosis in acute ischemic stroke patients[J]. Neuroepidemiology，2025，59（1）：31-42.
[69] YANG Y，HE P，ZHANG Y B. Systemic immune‐inflammation index predicts short‐term mortality in acute ischemic stroke with severe stenosis of internal carotid artery associated pneumonia[J/OL]. Brain Behav，2024，14（10）：e70047[2025-12-28]. https://doi.org/10.1002/brb3.70047.
[70] CAO X F，ZHU Q，XIA X，et al. The correlation between novel peripheral blood cell ratios and 90-day mortality in patients with acute ischemic stroke[J/OL]. PLoS One，2020，15（8）：e0238312[2025-12-28]. https://doi.org/10.1371/journal.pone.0238312.
[71] XIONG Y Y，LI S Y，WANG C J，et al. Chinese stroke association guidelines on reperfusion therapy for acute ischaemic stroke 2024[J]. Stroke Vasc Neurol，2025，10（5）：527-541.

急性缺血性卒中静脉溶栓中外周血炎症指标与预后的研究进展

Research Progress on Peripheral Blood Inflammatory Indices and Prognosis in Intravenous Thrombolysis for Acute Ischemic Stroke

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	何丹丹, 许淑红, 李姝雅. 急性缺血性卒中标准时间窗内新型静脉溶栓药物临床研究及展望[J]. 中国卒中杂志, 2026, 21(1): 24-29.
[2]	黄旭阳, 李润辉. 替奈普酶与阿替普酶治疗急性缺血性卒中短期神经功能恢复比较：线性混合效应模型分析[J]. 中国卒中杂志, 2026, 21(1): 31-37.
[3]	何丹丹, 冯宝玉, 刘改芬, 谷鸿秋, 李姝雅. 中性粒细胞与淋巴细胞比值对急性缺血性卒中静脉溶栓患者预后的预测价值：基于3项随机对照试验的个体患者数据分析[J]. 中国卒中杂志, 2026, 21(1): 38-47.
[4]	赵敏, 冯宝玉, 何丹丹, 王维聪, 李姝雅. 瑞替普酶与阿替普酶治疗急性缺血性卒中合并心律失常患者的有效性及安全性比较[J]. 中国卒中杂志, 2026, 21(1): 48-54.
[5]	宗黎霞, 付强, 杜万良. 儿童急性缺血性卒中静脉溶栓1例报道[J]. 中国卒中杂志, 2026, 21(1): 65-69.
[6]	殷子欣, 鲁珊珊, 施海彬, 吴飞云, 许晓泉. 不同期相CTA脑静脉引流对急性缺血性卒中患者血管内治疗后短期预后的预测价值[J]. 中国卒中杂志, 2026, 21(1): 70-77.
[7]	班淇琦, 王苇, 郭远, 厉阳, 苏星月, 瞿航. 构建目标检测模型在NCCT上检测急性小面积梗死灶的研究[J]. 中国卒中杂志, 2026, 21(1): 78-87.
[8]	中国卒中学会, 《单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识》专家组. 单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识[J]. 中国卒中杂志, 2026, 21(1): 88-98.
[9]	李欢, 于向明. 急性缺血性卒中DWI-FLAIR不匹配影像学判读研究进展[J]. 中国卒中杂志, 2025, 20(9): 1198-1202.
[10]	刘安利, 薛茜, 杨金水, 苗瑞瑞, 王欢欢. 抽吸取栓与支架取栓治疗急性缺血性卒中有效性及安全性的meta分析[J]. 中国卒中杂志, 2025, 20(8): 992-1005.
[11]	李子恒, 刘毅. 急性缺血性卒中静脉溶栓后早期抗血小板治疗的研究现状与展望[J]. 中国卒中杂志, 2025, 20(8): 1042-1050.
[12]	熊俞婷, 程爱春, 尹金风, 李子孝, 王春娟, 张静. BMI与急性缺血性卒中静脉溶栓患者院内结局的关系——基于中国卒中中心联盟登记数据库的分析[J]. 中国卒中杂志, 2025, 20(8): 1066-1072.
[13]	杨志进, 谭荃丹, 毛凤凯, 李朝晖, 陈晨, 李刚, 杨杰, 林亚鹏. 急性缺血性卒中超早期血压管理研究进展[J]. 中国卒中杂志, 2025, 20(7): 829-839.
[14]	胡燕琴, 王铄, 赵陶丽, 郭东兴, 李申, 金振波. 丁苯酞序贯治疗急性缺血性卒中有效性和安全性的meta分析[J]. 中国卒中杂志, 2025, 20(6): 753-761.
[15]	熊云云, 王拥军. 从起步到辉煌——中国卒中临床研究发展20年[J]. 中国卒中杂志, 2025, 20(5): 519-528.